- Home
- ZIMV vs AQST Comparison
ZIMV vs AQST Comparison
Compare ZIMV & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZIMV
- AQST
- Stock Information
- Founded
- ZIMV 2021
- AQST 2004
- Country
- ZIMV United States
- AQST United States
- Employees
- ZIMV N/A
- AQST N/A
- Industry
- ZIMV Biotechnology: Electromedical & Electrotherapeutic Apparatus
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- ZIMV Health Care
- AQST Health Care
- Exchange
- ZIMV Nasdaq
- AQST Nasdaq
- Market Cap
- ZIMV 262.9M
- AQST 272.9M
- IPO Year
- ZIMV N/A
- AQST 2018
- Fundamental
- Price
- ZIMV $8.77
- AQST $3.25
- Analyst Decision
- ZIMV Hold
- AQST Strong Buy
- Analyst Count
- ZIMV 2
- AQST 6
- Target Price
- ZIMV $10.00
- AQST $10.67
- AVG Volume (30 Days)
- ZIMV 146.2K
- AQST 1.6M
- Earning Date
- ZIMV 07-31-2025
- AQST 08-05-2025
- Dividend Yield
- ZIMV N/A
- AQST N/A
- EPS Growth
- ZIMV N/A
- AQST N/A
- EPS
- ZIMV N/A
- AQST N/A
- Revenue
- ZIMV $443,551,000.00
- AQST $54,228,000.00
- Revenue This Year
- ZIMV $1.96
- AQST N/A
- Revenue Next Year
- ZIMV $1.95
- AQST $45.71
- P/E Ratio
- ZIMV N/A
- AQST N/A
- Revenue Growth
- ZIMV N/A
- AQST 5.29
- 52 Week Low
- ZIMV $8.15
- AQST $2.12
- 52 Week High
- ZIMV $22.40
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- ZIMV 42.23
- AQST 54.57
- Support Level
- ZIMV $8.59
- AQST $3.20
- Resistance Level
- ZIMV $9.34
- AQST $3.61
- Average True Range (ATR)
- ZIMV 0.25
- AQST 0.28
- MACD
- ZIMV -0.04
- AQST -0.00
- Stochastic Oscillator
- ZIMV 12.50
- AQST 50.44
About ZIMV ZimVie Inc.
ZimVie Inc is focused on the dental and spine markets and their respective growth drivers such as implants, surgical tools, bone graft substitutes, spinal fusion implants, non-fusion alternatives, and digital care management solutions. Business is organized into two operating segments the spine products segment and the dental products segment.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.